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Summary
Objective: To compare the clinical effects of laterally wedged insoles and neutrally wedged insoles (used as control) in patients with medial
femoro-tibial knee osteoarthritis.
Methods: Study design: 24-month prospective randomized controlled study. Patients: Outpatients with painful medial femoro-tibial knee
osteoarthritis. Outcome measures: Patient’s overall assessment of disease activity (5 grade scale), WOMAC index subscales and
concomitant treatments. Statistical analysis: Performed as an intention-to-treat analysis, with the last observation carried forward (LOCF).
Main symptomatic criterion: Improvement in the patient’s assessment of activity (defined as a reduction of one grade or more at the end of
the study as compared to baseline, and no intra-articular injection or lavage during the 6 months previous to the last visit). Secondary criteria
for assessment: (a) Changes in the WOMAC subscales at month 24, and (b) concomitant therapies (analgesics, NSAIDs and intra-articular
injections or lavages). Structural criterion: Joint space width (JSW) at the narrowest point. Non-compliance was defined as intermittent or
lack of insole fitting at two consecutive visits. Compliance within groups was compared by using a life table analysis technique (Log-Rank).
Results: The baseline characteristics of the 156 recruited patients (41 males, 115 females, mean age 64.8 years) were not different in the
2 treatment groups. At year 2, there was no statistically significant difference between the 2 groups concerning the percentages of patients
with improvement in both global assessment of disease activity and in WOMAC subscales (pain, stiffness, function). The number of days with
NSAIDs intake was lower in the group with laterally wedged insoles than in the neutrally wedged group (71±173 days vs. 127±193 days,
P=0.003, Mann–Whitney test). The mean joint space narrowing rate did not differ between the two groups: 0.21±0.59 mm/year in the laterally
wedged group vs 0.12±0.32 mm/year in the neutrally wedged group. Compliance and tolerance were satisfactory. Compliance was different
between the 2 groups at month 24, with a greater frequency of patients who wore insoles permanently in the laterally wedged insole group
than in the other group (85.8% vs 71.9%, P=0.023).
Conclusion: This study failed to demonstrate a relevant symptomatic and/or structural effect of laterally-wedged insoles in medial
femoro-tibial OA. However, the reduced NSAIDs intake and the better compliance in the treatment group are in favor of a beneficial effect
of laterally-wedged insoles in medial femoro-tibial OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Knee osteoarthritis (OA) is a common condition having
an increased prevalence with age. Non-pharmacological
interventions, such as patient education, physical therapy,
weight management in overweight patients, orthoses or
assistive devices, are frequently and widely used and
strongly recommended1,2 in the management of patients
with osteoarthritis (OA). However, there is little evidence
that most of these interventions are effective because of
the small number of research studies on these inter-
ventions and the fundamental methodological flaws in
published studies3.
The aim of wedged insoles in medial knee OA is to
reduce the load on the medial joint surface (as opposed to
forcing the lateral joint surface to receive the load)4. Some
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factors suggest that laterally elevated wedged insoles
might be of interest in the treatment of medial femoro-tibial
knee OA. The potential clinical benefit of such insoles
would be to improve symptoms in painful knee OA patients,
to prevent long-term structural deterioration, or both. To
address this question, a prospective randomized controlled
two-year study, comparing the symptomatic and the struc-
tural effects of laterally wedged insoles and neutrally
wedged insoles (used as controls), in patients with medial
femoro-tibial knee OA, was undertaken.
Analysis was performed after 6 and 24 months of follow-
up. The 6 month symptomatic evaluation has been pub-
lished elsewhere5. We report the results obtained at month
24, not only in terms of symptomatic effects, but also in
terms of structural effects.
Patients and methods
PATIENTS
Outpatients fulfilling the American College of Rheumatol-
ogy criteria for the diagnosis of knee OA6 were recruited for
the study via three rheumatology departments. The clinical
criteria for inclusion were the presence of symptomatic
medial femoro-tibial OA, as defined by the presence of pain
on a daily basis for at least one month during the last three
months, pain of at least 30 (using an 0-100 visual analog
scale) after physical activities during the previous two days
and predominance of pain in the medial compartment of the
knee. The radiographic criterion for inclusion was evidence
of medial femoro-tibial OA on plain anteroposterior X-rays
(Kellgren and Lawrence grade ≥2).
Exclusion criteria were functional class of IV
(Steinbrocker), greater or similar reduction in lateral than
medial femoro-tibial joint space width on plain antero-
posterior X-rays, secondary knee OA7, hip OA, hallux
rigidus, valgus deformity of the midfoot, other symptomatic
deformity of the foot, advanced arthropathy of the hindfoot,
any disease treated with insoles within the past 6 months,
previous ankle arthrodesis, tibial osteotomy within the pre-
vious 5 years, knee joint lavage within the previous
3 months, intra-articular corticosteroid injection within the
previous month, changes in drug treatment for OA within
the previous week.
STUDY DESIGN
This prospective, multicenter, randomized, double-blind,
two-year, controlled study was conducted in order to com-
pare the symptomatic and structural effects of laterally
elevated (valgus) and neutrally wedged insoles (control), in
patients with medial compartment femoro-tibial knee OA.
The study protocol was approved by the Review Board of
Cochin Hospital (Paris, France).
Informed consent was obtained after the patients were
told that the study aimed to compare two kinds of insoles,
but not that one was presumed to be of greater efficacy
than the other. This is not a full informed consent, but this
approach was considered by the investigators as ethical
since it has been suggested that neutrally wedged insoles
might relieve some symptoms by absorbing impact load8.
This approach was approved by the Ethical Review Board
members.
STUDY COURSE
Each patient was recruited by a rheumatologist (one in
each center). The chiropodist (PK) then confirmed the
inclusion and randomized the patient. Symptomatic efficacy
was evaluated using standardized questionnaires mailed to
the patient. Any missing data were collected from the
patient by telephone by a research nurse who was unaware
of the randomization. Clinical follow-up evaluations were
made at months 1, 3, and then quarterly. During the
follow-up, the patients were treated either by their general
practitioner or their rheumatologist, who indicated any
concomitant therapy (analgesics, NSAIDs, intra-articular
injection, etc.).
A standardized antero-posterior weight-bearing standing
radiograph of the knee joints was made yearly.
TREATMENT AND COMPLIANCE
Patients were randomly assigned to one of two groups:
Bilateral laterally elevated (valgus) and bilateral neutrally
wedged insoles (Fig. 1). Insoles were made of Ledos
material (Socie´te´ Franc¸aise d’Orthopodie, Paris, France),
mounted on a leather strip. The Ledos material is made of
pure rubber with cork powder, and has a great capacity to
absorb impact load. The laterally elevated insoles were
individually modeled, with elevation depending on static
pedometer evaluation, but not on biomechanical evaluation
during walking.
Compliance and tolerance were evaluated at every
phone call by a research nurse. The patients were asked
whether they wore the insoles continuously, intermittently,
or not at all. Additionally, they evaluated tolerance on a
5-grade scale (discomfort: none/mild/moderate/severe/very
severe).
EVALUATION OF EFFICACY
Baseline evaluation
Age, gender, body mass index, Steinbrocker functional
class, pain, past history of knee OA and treatment were
noted. An antero-posterior knee radiograph and a femoro-
patellar joints radiograph were made. The Kellgren and
Lawrence (KL) grade9 and the joint space width (using a
0.5 mm-graduated clear plastic ruler) of the medial femoro-
tibial joint were determined. The presence of OA in homo-
lateral femoro-patellar and/or lateral femoro-tibial joints and
in contralateral femoro-patellar and/or femoro-tibial joints
was noted.
Symptomatic outcome measures
The patient’s overall assessment of disease activity
during the previous two days (0–4 grade scale; activity:
none/mild/moderate/severe/very severe), the Western
Ontario and McMaster Universities (WOMAC) index11,
were obtained at baseline and at months 1, 3, and then
quarterly. At each evaluation, the patients were also asked
how many days during the previous three months he/she
needed concomitant treatment (analgesics, NSAIDs)
because of a painful condition related to his/her knee OA.
Structural outcome measures
The structure of the OA knee was evaluated by radiogra-
phy once a year or at the end of follow-up. Antero-posterior
radiograph of the knee joints were obtained with patients in
a weight-bearing position, joint fully extended, standing at
1 m from the X-ray source, with a constant and reproduc-
ible foot position (foot map, feet internal rotation 10°), and
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with the X-ray beam centered on joint space and oriented
parallel to the tibial plateau. At the end of the study, the
films of the same patient (baseline, one-year and two-year
follow-up) were analyzed in the same session by a single
observer (TP) who was unaware of the insole treatment
and of the sequence of the radiographs. The observer
determined the location of the narrowest point of the joint
space width (JSW) on the radiograph of a given knee
(minimal JSW), then transferred this point to the other films
of the set being measured. The anatomic limits for the
measurement of the JSW were the bone contour of the
medial tibial plateau (the anterior side if the anterior and
the posterior sides were not correctly aligned) and the bone
contour of the medial femoral condyle. Both limits were
marked with a short stroke of a specific pencil. The distance
between these limits was measured using a 0.1 mm-
graduated magnifying glass. In case of reduced digitized
film (N=6; 4%), the femoral epiphysis and diaphysis widths
were measured on digitized and non-digitized radiographs
of the same set to calculate the differential ratio. The JSW
of the digitized film was then converted according to this
ratio. These JSW measures, being more accurate than
those collected at the baseline visit, were the ones used for
analysis. The intra-observer (TP) reproducibility of this
technique evaluated for the ongoing study was considered
as acceptable (intraclass correlation coefficient, 0.993
[0.988; 0.995] (Anova)).
STATISTICAL ANALYSIS
Symptomatic data
Analysis was made using an intention-to-treat approach,
with the last observation carried forward (LOCF). The main
criterion for assessment of efficacy was chosen prior to the
study and defined as an improvement in the patient’s
overall assessment of disease activity at year 2 compared
to baseline. Improvement was defined as a reduction of
one grade or more from baseline, and absence of steroid or
hyaluronate intra-articular injection or articular lavage dur-
ing the previous 6 months. The presence or not of improve-
ment was compared between the two groups using a Chi2
test. The expected treatment effect was a difference of 20%
between groups in the percentage of patients improved,
using the patient’s global assessment as primary outcome.
This criterion was chosen arbitrary before the study started.
A sample size of 70 patients in each group was required to
detect such a difference, with a significance level of 95%
and a power of 80%.
The patient’s overall assessment of disease activity was
also compared between the two groups using the change
between final and baseline and areas under the curve
analyses. For these analyses, the 0-IV grade scale was
converted into a 0–100 scale (0=0, I=25, II=50, III=75 and
IV=100).
The baseline characteristics of patients were compared
between the groups with and without an improvement of
the patient’s overall assessment of disease activity at year
2. Evaluated variables were: age, gender, body mass
index, Steinbrocker functional class, pain (VAS), patient’s
overall assessment of disease activity, WOMAC subscales,
KL radiographic stage, joint space width, presence of a
homolateral femoro-patellar OA, a homolateral lateral
femoro-tibial OA, a contralateral femoro-patellar, medial
and lateral femoro-tibial OA, presence of other localization
of OA (hand, neck, back, hip), mean analgesics and
NSAIDs intake during the previous 3 months, treatment
with ‘disease modifying drugs’ (yes or no).
Improvement in the WOMAC index subscales was
defined as a decrease of ≥30% compared to baseline with
no corticosteroid or hyaluronate intra-articular injections
nor joint lavage during the previous 6 months. WOMAC
index subscales were also compared between the two
groups with the change between final and baseline and
Fig. 1. The neutrally and laterally wedged insoles.
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areas under the curve analyses. In case of local treatment
(i.e. infiltration, lavage) during the previous quarter, the
data previous to the observed data was reported instead.
Intraclass change between baseline and final was calcu-
lated for global assessment and WOMAC subscales
(Student’s test or Mann–Whitney’s test).
Each variable distribution was evaluated with the
Kolmogorov–Smirnov test, and since the distribution was
not always normal, the Chi-2 test and Student’s t-test,
or Fisher’s test and Mann–Whitney’s test were used
accordingly.
The other secondary outcome measure was the evalu-
ation of concomitant therapies. The number of days with
analgesics and NSAIDs intake during the entire study were
compared between the two groups using a Mann–Whitney
test. The number of intra-articular injections or joint lavages
during follow-up was compared between the two treatment
groups using a Mann–Whitney test. The need of intra-
articular injections within groups was compared by using a
life table analysis technique (Log-Rank test).
Compliance was evaluated quarterly. Non-compliance
was defined as having worn the insoles intermittently or not
at all, as reported at two consecutive visits. Compliance
within groups was compared by using a life table analysis
technique (Log-Rank test).
Structural data
The primary efficacy end-point of the study was the
radiographic progression of OA, expressed as the magni-
tude of the narrowing of the joint, calculated as the joint
space narrowing rate (in mm/year) between baseline and
final.
Radiographic progression was also assessed by the
proportion of patients with radiographic worsening. In order
to define a relevant cut-off permitting to switch the con-
tinuous variable ‘change in joint space width’ into a dichoto-
mous variable ‘progression yes/no’, two approaches were
used:
+ The first was to consider a threshold of 0.5 mm as
previously reported in the literature10–12.
+ Because of a potential inter-study and/or inter-observer
variability, we performed an ancillary study aimed at
defining the cut-off. For this purpose, 30 random pairs
of medial femoro-tibial OA knee films available within
this study were selected and analyzed by the reader
(TP). This same analysis was performed a second time
after one month, blindly to the results of the first
analysis. Joint space width was measured at the nar-
rowest point with a 0.1 mm graduated magnifying
Screened: n = 182
Eligibility criteria not met / Patient’s refusal: n = 26
Neutrally-wedged insole
not qualified n = 0
qualified n = 74
Laterally-wedged insole
not qualified n = 0
qualified n = 82
Withdrawn………………….  n = 10
•  Sudden death…………….  n = 1
•  Surgery…………………...  n = 0
•  Personal reasons………….  n = 3
•  Lost to follow-up…………  n = 4
•  Others……………………. n = 2
Completed 1 year trial: n = 64 Completed 1 year trial: n = 70
Withdrawn………………….  n = 12
•  Sudden death…………….  n = 1
•  Surgery…………………...  n = 4
•  Personal reasons………….  n = 2
•  Lost to follow-up…………  n = 3
•  Others……………………. n = 2
Withdrawn………………….  n = 13
•  Surgery…………………...  n = 1
•  Personal reasons………….  n = 2
•  Lost to follow-up…………  n = 6
•  Others…………………….  n = 4
Completed the 2-year trial: n = 51 Completed the 2-year trial: n = 55
Withdrawn………………….  n = 15
•  Surgery…………………...  n = 1
•  Personal reasons………….  n = 6
•  Lost to follow-up…………  n = 6
•  Others…………………….  n = 2
Randomized: n = 156
Fig. 2. Course of the 2-year randomized trial.
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glass. The change observed between the 30 pairs of
films at the first reading was −0.28±0.68 mm. At the
second reading, it was −0.24±0.68 mm. The change
between the two changes was −0.03±0.16 mm. The
smallest detectable difference (SDD) corresponds to
the smallest difference on JSW exceeding the
measurement error and was in this case 0.3 mm13.
Thus, the progression was calculated in the 2 groups of
the ongoing study by using a life table analysis technique
(Log Rank test) in which the event was defined by a joint
space narrowing of at least 0.3 mm or of at least 0.5 mm.
Results
One hundred and fifty six patients (41 males, 115
females, mean age 65±10 years) were included. After
randomization, patients were assigned to neutrally wedged
or to laterally wedged insoles (74 and 82 patients respect-
ively). Fig. 2 summarizes the study course. During the
first year, sudden death occurred in two patients, three
patients underwent total knee arthroplasty (TKA) and one
osteotomy (all four from the laterally wedged group), five
patients decided to withdraw from the study for personal
reasons and four patients due to intolerance or inefficacy,
and 9 were lost to follow-up. During the second year,
2 patients underwent surgery (TKA), 4 withdrew for intoler-
ance or inefficacy, 8 withdrew for personal reason, and
12 were lost to follow-up.
The main baseline characteristics of the 156 randomized
patients are summarized in Table Ia. The only difference
between the two groups was a greater proportion of women
in the neutrally wedged group (82% vs 63%). The structural
baseline data (Table Ib) were available only for 148
patients: 3 patients did not return the X-ray films after
undergoing surgery, 2 X-ray films were lost and 3 could not
be interpreted.
SYMPTOMATIC DATA
The patients’ overall assessments of disease activity are
shown in Table II.
At year 2, the global assessment was improved in 87
patients, including 27/74 patients (36.5%) in the neutrally
wedged insole group and 33/82 patients (40.2%) in the
laterally wedged insole group (P=0.63). Similar results
were obtained at months 6, 12 and 18. Table III summa-
rizes the global assessment changes in intent-to treat
analysis within each group and their comparison with the
Mann–Whitney’s test.
The WOMAC index scores are shown in Table II. At
year 2, the WOMAC pain subscale was improved in 21/74
patients (28.4%) and in 20/82 patients (24.4%) in the
neutrally and the laterally wedged insole groups, respect-
ively (P=0.57) (Chi-2 test). Similar results were obtained
at months 6, 12 and 18, and with the WOMAC joint
stiffness and physical functioning subscales. Comparison
between the 2 groups using delta M24-M0 and areas
under the curve did not show any significant difference
(Table III).
The intraclass change between baseline and final for the
global assessment was significant in the laterally wedged
group (mean±S.D.: −5.79±26.1) but not in the neutrally
wedged group (−4.73±22.5).
The need for concomitant treatment during the study is
shown in Table IV. At baseline, there was no difference
between the two groups. At year 2, there was a statistically
significant difference in NSAIDs intake between the two
groups (P=0.003). The trend toward a reduction in anal-
gesic intake in the laterally-wedged insole group observed
at month 65 was not confirmed at the end of the study.
Forty-five patients were treated with intra-articular injec-
tions (corticosteroids, hyaluronate, or articular lavage) dur-
ing the follow-up (Fig. 5). Among these, 23 were in the
neutrally wedged insole group and 22 in the laterally
wedged insole group (P=0.19, log-rank test).
Table Ia
Main baseline characteristics of the patients
a: Baseline clinical characteristics of the 156 randomized patients
Parameters Neutrally wedged insole group Laterally wedged insole group
Patients (number) 74 82
Demographic data
*Age (mean years±S.D.) 65.6±9.9 64.0±10.8
*Gender (male/female) 13/61 28/54
*Body mass index (mean kg/m2±SD) 28.5±5.3 29.0±5.6
*Disease duration (years±SD) 6.0±5.3 6±7.4
Symptomatic data
*Steinbrocker functional class
Class I (% of patients) 5.4.% 7.4%
Class II (% of patients) 55.4% 59.3%
Class III (% of patients) 39.2% 33.3%
*Pain (mean mm±S.D.) 55.6±18.4 53.6±16.1
Table Ib
Main baseline characteristics of the patients
b: Baseline structural characteristics of the 148 randomized patients with available baseline radiograph
Parameters Neutrally wedged insole group Laterally wedged insole group
Patients (number) 69 79
Evaluated medial knee joint (right/left) 37/32 46/33
Joint space width of the evaluated medial knee joint (mean mm±S.D.) 3.8±1.3 3.6±1.5
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Compliance and tolerance were satisfactory. Non-
compliance was defined as wearing the insoles intermit-
tently or not at all as reported at two consecutive visits.
Compliance was different between the 2 groups at month
24, with a greater frequency of patients who wore insoles
permanently in the laterally wedged insole group than in the
other group (85.8%±8.2 vs 71.5±10.4%; P=0.02, log-rank
test) (Fig. 3). At the end of the study, intolerance was the
Table II
Baseline characteristics and changes in the symptomatic variables after 2 years, by treatment group
Neutrally wedge insole group Laterally wedged insole group
Baseline
assess-
ment
12-month
assess-
ment
24-month
assess-
ment
Baseline
assess-
ment
12-month
assess-
ment
24-month
assess-
ment
Global patient’s
assessment (0–IV grade
scale)† (number of
patients)
0 0 0 1 0 1 2
I 4 11 13 4 19 18
II 40 37 34 36 36 30
III 27 23 22 39 15 20
IV 3 3 4 3 11 12
% of improved patients* 30.1% 36.5% 43.9% 40.2%
WOMAC pain subscale
(0–100 scale)
mean 52.2 47.9 48.2 53.5 50.1 51.0
S.D. 17.2 19.4 19.9 17.0 24.8 26.7
% of improved patients* 20.5% 28.4% 26.8% 24.4%
WOMAC joint stiffness
subscale (0–100 scale)
mean 50.3 50.0 50.0 51.8 48.9 51.8
S.D. 18.9 18.9 19.7 21.1 27.5 27.3
% of improved patients* 27.4% 18.9% 32.9% 29.3%
WOMAC physical
functioning subscale
(0–100 scale)
mean 50.0 48.4 50.4 48.8 49.0 50.0
S.D. 19.1 19.2 21.1 18.9 24.7 26.4
% of improved patients* 19.2% 20.3% 29.3% 22.0%
†Overall patient’s assessment: 0=none; I=mild; II=moderate; III=severe; IV=very severe.
*Percentage of patients with improvement in overall assessment of disease activity (defined as a reduction of 1 grade or more from
baseline, and no corticosteroids or hyaluronate intra-articular injection or articular lavage during the follow-up) or with an improvement in
WOMAC subscales (defined as a decrease ≥ 30% from baseline, and no corticosteroid or hyaluronate intra-articular injections or joint lavage
during the follow-up).
Table III
Baseline and final values of the following outcome variables: global patient’s assessment, WOMAC pain subscale, WOMAC stiffness
subscale, WOMAC function subscale, by treatment group; change between final and baseline by treatment group.
Baseline (M0) M 24 M24-M0
N L N L N L P
Global assessment (0–100 scale) m 59.8 62.5 55.1 56.7 −4.7 −5.8 P=0.38*
S.D. 16.5 16.3 21.1 26.1 22.5 26.1
WOMAC pain subscale (0–100 scale) m 52.2 53.5 48.2 51.0 −3.9 −2.6 P=0.37**
S.D. 17.2 17.0 19.9 26.7 19.7 24.3
WOMAC stiffness subscale (0–100 scale) m 50.3 51.8 50.0 51.8 0.4 1.2 P=0.25
S.D. 18.9 21.1 19.7 27.3 16.8 25.6
WOMAC function subscale (0–100 scale) m 50.0 48.8 50.4 50.0 0.4 1.2 P=0.25
S.D. 19.1 18.9 21.1 26.4 16.8 25.6
*Mann–Whitney test
**Chi2 test
N=Neutrally wedged insole group, L=Laterally wedged insole group, AUC=Area under the curve, RMVA=Repeated measures variance
analysis, m=mean, sd=standard deviation
Table IV
Concomitant treatment intake during the 2-year study, by treatment group (intent-to treat analysis)
Neutrally wedged
insole group
Laterally wedged
insole group
Mann–
Whitney test
Analgesics Number of days with analgesic intake during the
2-year study (mean)
161 163 P=0.40
sd 221 235
NSAIDs Numbers of days with NSAID intake during the
2-year study (mean)
168 71 P=0.003
S.D. 194 173
Intra articular injection total 23 22 P=0.19
mean (number of injection/patient) 0.31 0.27
S.D. 0.60 0.65
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reason for no longer wearing insoles for two patients in both
groups.
STRUCTURAL DATA
One hundred and ten patients had a least two knee
radiographs allowing joint space narrowing rate measure-
ment. In this population, the mean value of the joint space
narrowing rate did not differ between the two groups:
0.21±0.59 mm/year (mean ± S.D.); 0.13 mm/year (median)
[min:−3.08; max: 0.55] in the laterally wedged group versus
0.12±0.32 mm/year; 0.08 mm/year [min: −0.8; max: 0.91] in
the neutrally wedged group (P=0.45, Mann–Whitney test).
The occurrence of radiographic progression during the
study was similar in both groups. At year 2, there was
43.2%±14.9 and 75.4%±16.4 of ‘0.5 mm-progression’ and
‘0.3mm-progression’ respectively in the laterally wedged
insole group vs 37.2%±15.7 and 62.8%±14.9 in the
neutrally wedged group (P=NS, log rank test) [Fig. 4 (a)
and 4(b)].
Discussion
This study failed to demonstrate a relevant symptomatic
and/or structural effect of laterally wedged insoles in medial
femoro-tibial osteoarthritis. However, the lesser NSAIDs
intake and the greater compliance in the laterally wedged
group are in favor of a beneficial effect of laterally wedged
insoles in the management of knee osteoarthritis, par-
ticularly since adherence to treatment interventions in
osteoarthritis is known to be poor14.
These results corroborate those of the 6 month-
analysis5. However, this apparent lack of effect is in con-
tradiction with several previous studies suggesting
effectiveness of laterally wedged insoles in patients with
medial knee OA15–18. Three main hypotheses could explain
this discrepancy: first, laterally wedged insoles are effec-
tive, but this study failed to demonstrate it; second, laterally
wedged insoles are not effective; and third, laterally wedged
insoles are effective but only in a subgroup of patients.
Let us consider the first hypothesis, i.e. this study failed
to demonstrate the treatment efficacy. First of all, the
control group (i.e.,neutrally wedged group) was not a
placebo group, since patients wore neutrally wedged
insoles that might have relieved some symptoms through
absorbing impact load8, resulting in a possible loss of
statistical power. Unfortunately, it was difficult to proceed
differently in this prospective controlled study.
Also, as recommended by the American College of
Rheumatology (ACR) and the European League Against
Rheumatism (EULAR), the concomitant treatments were
maintained19,20,7. In other words, systemic treatment modi-
fications, intra-articular injections (corticosteroids, hyaluro-
nate, lavage), etc. were allowed during the follow-up.
These modifications, although taken into account in the
analysis, may have lessened the positive results of the
insole therapy. The patients used analgesics and NSAIDs
when necessary. Some improved patients may have
decreased the doses of these drugs, resulting in less
improvement attributed to the insoles. The results concern-
ing NSAIDs consumption are in favor of this hypothesis,
since at year 2 there was a statistically significant and a
clinically meaningful reduction in NSAIDs intake in the
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Fig. 3. Compliance by treatment group during the 2-year study.
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laterally wedged insole group compared to the neutrally
wedge insole group (71±173 vs 168±194 days of intake,
P=0.003). Conversely, the results concerning analgesics
consumption did not confirm this hypothesis.
The degree of wedging can be evoked as another reason
to explain the failure of the study to demonstrate insole
efficacy. In order to obtain the optimal degree of wedging,
individual modeling could have been performed according
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Fig. 4. Proportion of patients with radiographic progression of at least 0.5 mm during the study.
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to biomechanical evaluation during walking, rather than
according to static pedometer evaluation.
Finally, one can consider whether the ‘traditional’ clinical
trial design is suitable for non-pharmacological treatment
trials. This study design followed the recommendations of
the task force of the Osteoarthritis Research Society and
the Group for the Respect of Ethics and Excellence in
Science (GREES)20,7. It is worth noting that no placebo
effect was observed. The change observed was less than
the placebo effect usually observed in pharmacological
treatment trials.
Studies analyzing the effects of orthotic interventions are
of poor quality3 and the trials are difficult to compare. None
evaluated the structural effects of insoles. The radiographic
progression of the laterally wedged insole group is similar
to that observed in the placebo group of pharmacological
trials. Knee osteoarthritis may be not a relevant human
model to detect radiological progression, since this change
is minor1.
Let us now consider the second hypothesis, namely that
laterally wedged insoles are indeed not effective in patients
with medial knee OA. Most trials did demonstrate a positive
symptomatic outcome as a result of orthotic intervention in
the short term, albeit none of these previous studies was
prospective, randomized or controlled15–18. The discrep-
ancy between the results of our double-blind randomized
study and those of previous studies might be because of
the difference in study design, with more convincing results
from the double-blind randomized study. In this study, the
lack of significant difference between groups in the primary
and in most secondary outcomes does not support the use
of laterally-wedged insoles in medial knee OA.
In this study, patient’s overall assessment was a priori
chosen as the main assessment criterion. This variable is
one of the 3 included in the core set recommended by
OMERACT21. However, the OARSI society2 suggests that
pain, obtained using VAS, Likert scale, or WOMAC pain
subscale, should be used as primary outcome. In this
study, using the WOMAC pain subscale as the primary
symptomatic outcome would not have changed the results
or the conclusion.
Moreover, the results suggest a trend toward slower
progression in the neutrally wedged insole group than in
the laterally wedged insole group (0.12±0.32 mm/year and
0.21±0.59 mm/year respectively). However, there was no
statistically significant difference, and the expression of the
results in terms of responders and/or ‘progression’ does not
support a better symptomatic effect of neutral insoles when
compared to the laterally elevated ones.
In the third hypothesis, we stated that laterally wedged
insoles could be effective in subgroups of patients only. In a
recent study, Toda et al.22 suggest that insoles with subtalar
strapping (different than the ones used in our study) are
more effective for younger medial compartment OA
patients and for those with a higher lower-extremity-lean-
body mass per body weight. In our study, there were no
factors to support the hypothesis that laterally wedged
insoles are effective only in subgroups of patients. Above
all, although it has been suggested that laterally wedged
insoles are more effective in patients with mild or moderate
than in those with advanced structural involvement15,16,
there was no significant correlation between the presence
of an improvement in the patient’s overall assessment and
the baseline KL radiographic stage nor the baseline joint
space width. The only variables that were related to the
presence of an improvement in the patient’s overall assess-
ment were the baseline overall assessment and the
baseline WOMAC function subscale.
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54 T. Pham et al.: Insoles in medial knee osteoarthritis
In conclusion, laterally wedged insoles were well toler-
ated by patients with medial knee OA. Despite the lack of
significant difference between groups in the primary and in
most secondary outcomes, the lesser NSAIDs intake and
the better compliance might be considered as indirect
support for some efficacy of the laterally wedged insoles,
suggesting a symptomatic drug-sparring effect. Laterally
wedge insoles seem to have no influence on radiographic
progression. Other studies on other sets of patients would
be of interest to confirm these results, and to discuss
the relevance of such design study for evaluating non
pharmacological therapies.
Acknowledgements
This work was supported in part by a “Programme
Hospitalier de Recherche Clinique” (AOM 97 184) from the
French Health Ministry.
The authors gratefully thank Florence Tubach, MD, for
her assistance.
References
1. Pendleton A, Arden N, Dongados M, Doherty M,
Banwarth B, Bijlsma J. et al. EULAR recommenda-
tions for the management of knee osteoarthritis.
Report of a task force of the Standing Committee for
International Clinical Studies Including Therapeutic
trials (ESCISIT). Ann Rheum Dis 2000;59:936–944.
2. Hochberg MC, Altman RD, Brandt KD, Moscowitz RW.
Design and conduct of clinical trials in osteoarthritis:
preliminary recommendations from a task force of the
Osteoarthritis Research Society. J Rheumatol 1997;
24:792–4.
3. Hurley M, Walsh N. Physical, functional and other
non-pharmacological interventions for osteoarthritis.
Best Pract Res Clin Rheumatol 2001;15:569–81.
4. Yasuda K, Sasaki T. The mechanics of treatment of the
osteoarthritic knee with a wedged insole. Clin Orthop
1987;215:162–72.
5. Maillefert JF, Hudry C, Baron G, Kieffert P, Bourgeois
P, Lechevallier D, et al. Laterally elevated wedged
insoles in the treatment of medial knee osteoarthritis:
a prospective randomized controlled study. Osteo-
arthritis Cart 2001;9:738–45.
6. Altman R, Asch E, Bloch D, Borenstein K, Brandt K,
Christy W, et al. Development of criteria for the
classification and reporting of osteoarthritis. Classifi-
cation of osteoarthritis of the knee. Arthritis Rheum
1986;29:1039–49.
7. Group for the Respect of Ethics and Excellence in
Science (GREES). Recommendations for the regis-
tration of drugs used in the treatment of osteoarthritis.
Ann Rheum Dis 1996;55:552–7.
8. Dieppe P, Buckwalter JA. Management of limb joint
osteoarthritis. In: Klippel JH, Dieppe PA, Eds.
Rheumatology, 2nd edn. London Philadelphia St
Louis Sydney Tokyo: Mosby 1998;8.9.1.
9. Kellgren JH, Lawrence JS. Radiological assessment of
osteoarthritis. Ann Rheum Dis 1957;16:494–502.
10. Lequesne M, Brandt K, Bellamy N, Moskowitz R,
Menkes CJ, Pelletier JP, et al. Guidelines for testing
slow acting drugs in osteoarthritis. J Rheumatol
Suppl. 1994;41:65–71 discussion 72–73.
11. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune
E, Bruyere O, et al. Long-term effects of glucosamine
sulphate on osteoarthritis progression: a randomised,
placebo-controlled clinical trial. Lancet 2001;357:
251–6.
12. Dougados M, Nguyen M, Berdah L, Mazieres B,
Vignon E, Lequesne M, ECHODIAH Investigators
Study Group. Evaluation of the structure-modifying
effects of diacerein in hip osteoarthritis: ECHODIAH,
a three-year, placebo-controlled trial. Evaluation of
the Chondromodulating Effect of Diacerein in OA of
the Hip. Arthritis Rheum 2001;44:2539–47.
13. Ravaud P, Giraudeau B, Auleley GR, Edouard-Noel R,
Dougados M, Chastang C. Assessing smallest de-
tectable change over time in continuous structural
outcome measures: application to radiological
change in knee osteoarthritis. J Clin Epidemiol 1999;
52:1225–30.
14. Carr A. Barriers to the effectiveness of any intervention
in OA. Best Pract Res Clin Rheumatol 2001;15:
645–56.
15. Ogata K, Yasunaga M, Nomiyama H. The effects of
wedged insoles on the thrust of osteoarthritic knees.
Int Orthop 1997;21:308–12.
16. Sasaki T, Yasuda K. Clinical evaluation of the treat-
ment of osteoarthritic knees using a newly designed
wedged insole. Clin Orthop 1987;221:181–7.
17. Keating EM, Faris PM, Ritter MA, Kane J. Use of
lateral heel and sole wedges in the treatment of
medial osteoarthritis of the knee. Orthop Rev 1993;
22:921–4.
18. Toda Y, Segal N, Kato A, Yamamoto S, Irie M. Effect of
a novel insole on the subtalar joint of patients with
medial compartment osteoarthritis of the knee. J
Rheumatol 2001;28:2705–10.
19. Recommendations for the medical management of
osteoarthritis of the hip and knee: 2000 update.
American College of Rheumatology Subcommittee
on Osteoarthritis Guidelines. Arthritis Rheum
2000;43:1905–1915.
20. Altman R, Brandt K, Hochberg M, Moskowitz R, for the
Task Force. Design and conduct of clinical trials in
patients with osteoarthritis: recommendation from a
task force of the Osteoarthritis Research Society.
Osteoarthritis Cart 1996;4:217–43.
21. Bellamy N, Buchanan WW, Goldsmith CH, Campbell
J, Stitt LW. Validation study of WOMAC: a health
status instrument for measuring clinically important
patient relevant outcomes to antirheumatic drug
therapy in patients with osteoarthritis of the hip or
knee. J Rheumatol 1988;15:1833–40.
22. Toda Y, Segal N, Kato A, Yamamoto S, Irie M. Corre-
lation between body composition and efficacy of
lateral wedged insoles for medial compartment
osteoarthritis of the knee. J Rheumatol 2002;29:
541–5.
Osteoarthritis and Cartilage Vol. 12, No. 1 55
